Anavex Life Sciences Corp. (NASDAQ:AVXL)

Speculative Pick (2% max allocation would be wise); Sharing my number one stock pick once again; Where many others have failed and gone home, Anavex continues to march towards the first effective treatment for dementia in history; Stock recently fell after they reported positive Phase I results for another candidate in their pipeline (3-71); Investors are too quick to fold their hands; They forget that she is close to completing Phase III testing for her flagship candidate 2-73; 100% of trial study patients have voluntarily signed up for continued treatment under extended long term study protocols since Phase I; Study goals exceed required FDA data points; They’ve also received positive feedback from preliminary FDA reviews with zero change recommendations offered; I predict full FDA approval before year's end; Stock likely to move long before then regardless of what the general market is doing

Shrinking deficit and improving technicals.